Abstract: bjective  This study aimed to investigate the methylation levels of PCDHGB7 in lung adenocarcinoma tissues using data from The Cancer Genome Atlas (TCGA) and to explore its association with clinical pathological features of lung adenocarcinoma, as well as its efficacy in prognostic assessment. Methods  Methylation data of PCDHGB7 from 473 lung adenocarcinoma patients and 32 normal controls in the TCGA database were analyzed to assess differences in methylation levels. This analysis was combined with clinical pathological and prognostic data to evaluate the correlation between methylation levels and clinical pathological features, as well as overall survival prognosis. Results  PCDHGB7 exhibited significantly high methylation levels in lung adenocarcinoma tissues (P<0.001), demonstrating a strong discriminative ability for tumor tissues (AUC = 0.926, P<0.001). Methylation levels were significantly associated with gender (P = 0.047) and tumor T stage (P = 0.013). Univariate Cox regression analysis identified key sites of PCDHGB7 associated with prognosis, leading to significant differences in overall survival prognosis among patient groups (P = 0.0099). Conclusion  PCDHGB7 shows significantly high methylation in lung adenocarcinoma, correlating with the malignancy of tumor lesions and possessing certain prognostic predictive capabilities.